Showing results (41-50 of 1,983) with videos related to
Sort By:
Pageof 199
BMC Cancer|September 11, 2016
53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cellsRuoxi Hong, Fei Ma, Weimin Zhang, et al.Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|July 18, 2014
[Efficacy and safety of trastuzumab plus different chemotherapy regimens in treatment of the patients with HER-2-positive advanced breast cancer]Jihong Guo, Binghe Xu, Fei Ma, et al.The International Journal of Biological Markers|July 22, 2014
HER2 as a predictive factor for successful neoadjuvant anthracycline chemotherapy of locally advanced and early breast cancerJiayu Wang, Binghe Xu, Peng Yuan, et al.Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|January 11, 2024
Breast cancer: Epidemiology, risk factors and screeningHangcheng Xu, Binghe XuPlos One|August 21, 2015
Association of Pretreatment Anemia with Pathological Response and Survival of Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Population-Based StudyWenjie Zhu, Binghe XuCancer|July 26, 2020
Current clinical trials on breast cancer in China: A systematic literature reviewYing Fan, Binghe XuFrontiers of Medicine|November 11, 2020
Overcoming resistance to endocrine therapy in hormone receptor-positive human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a meta-analysis and systemic review of randomized clinical trialsWenjie Zhu, Binghe XuCancer Communications (London, England)|September 8, 2022
Breast cancer: an up-to-date review and future perspectivesRuoxi Hong, Binghe XuPlos One|August 8, 2014
MicroRNA-21 identified as predictor of cancer outcome: a meta-analysisWenjie Zhu, Binghe XuSignal Transduction and Targeted Therapy|October 23, 2019
Targeted therapeutic options and future perspectives for HER2-positive breast cancerJiani Wang, Binghe XuPageof 199